Search Results - "Shingyoji, Masato"

Risk factors for type I leptomeningeal metastasis derived from non-small cell lung cancer and the impact of treatment for brain metastases on its development.

Authors: Iuchi, Toshihiko Shingyoji, Masato Mizuno, Satoko et al.

Source: Neuro-Oncology Practice. Jun2025, Vol. 12 Issue 3, p448-457. 10p.

The significance and robustness of a plasma free amino acid (PFAA) profile-based multiplex function for detecting lung cancer.

Authors: Shingyoji, Masato Iizasa, Toshihiko Higashiyama, Masahiko et al.

Source: BMC Cancer. 2013, Vol. 13 Issue 1, p1-10. 10p. 1 Diagram, 5 Charts, 2 Graphs.

Retrospective analysis of lung cancer patients treated with supportive care alone.

Authors: Ashinuma, Hironori Shingyoji, Masato Yoshida, Yasushi et al.

Source: International Journal of Clinical Oncology. Jun2017, Vol. 22 Issue 3, p455-460. 6p.

Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations.

Authors: Iuchi, Toshihiko Shingyoji, Masato Itakura, Meiji et al.

Source: International Journal of Clinical Oncology. Aug2015, Vol. 20 Issue 4, p674-679. 6p.

This result is not displayed to guests.
Login for full access.

Spectrum Analysis of Endobronchial Ultrasound for Prediction of Lymph Node Metastasis in Patients With Lung Cancer.

Authors: Nakajima, Takahiro Shingyoji, Masato Anayama, Takashi et al.

Source: CHEST. Oct2012 Supplement, Vol. 142, p867A-867B. 1p.

A Case of Long-Term Survival after Checkpoint Inhibitor Pneumonitis in a Patient with Squamous Cell Lung Cancer.

Authors: Ashinuma, Hironori Mizuno, Satoko Yoshida, Yasushi et al.

Source: Case Reports in Oncological Medicine. 12/27/2019, p1-5. 5p.

Cytotoxicity of replication-competent adenoviruses powered by an exogenous regulatory region is not linearly correlated with the viral infectivity/gene expression or with the E1A-activating ability but is associated with the p53 genotypes.

Authors: Suguru Yamauchi Boya Zhong Kiyoko Kawamura et al.

Source: BMC Cancer. 9/5/2017, Vol. 17, p1-12. 12p. 6 Charts, 2 Graphs.

Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways.

Authors: Kengo Shimazu Yuji Tada Takao Morinaga et al.

Source: BMC Cancer. 5/2/2017, Vol. 17, p1-14. 14p. 1 Black and White Photograph, 1 Chart, 4 Graphs.

Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma.

Authors: Yuanyuan Jiang Boya Zhong Kiyoko Kawamura et al.

Source: BMC Cancer. 7/12/2016, Vol. 16, p1-15. 15p. 2 Diagrams, 3 Charts, 5 Graphs.

Fas Ligand DNA Enhances a Vaccination Effect by Coadministered DNA Encoding a Tumor Antigen through Augmenting Production of Antibody against the Tumor Antigen.

Authors: Zhong, Boya Ma, Guangyu Sato, Ayako et al.

Source: Journal of Immunology Research. 2/18/2015, Vol. 2015, p1-7. 7p. 1 Color Photograph, 3 Graphs.

Zoledronic Acid Produces Combinatory Anti-Tumor Effects with Cisplatin on Mesothelioma by Increasing p53 Expression Levels.

Authors: Okamoto, Shinya Jiang, Yuanyuan Kawamura, Kiyoko et al.

Source: PLoS ONE. Mar2013, Vol. 8 Issue 3, p1-9. 9p.

Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC.

Authors: Sugawara, Shunichi Nakagawa, Kazuhiko Yamamoto, Nobuyuki et al.

Source: International Journal of Clinical Oncology. May2019, Vol. 24 Issue 5, p485-493. 9p.

Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia.

Authors: Kato, Yuki Udagawa, Hibiki Matsumoto, Shingo et al.

Source: Lung Cancer (01695002). Nov2024, Vol. 197, pN.PAG-N.PAG. 1p.

Spectrum Analysis of Endobronchial Ultrasound Radiofrequency of Lymph Nodes in Patients With Lung Cancer.

Authors: Takahiro Nakajima Masato Shingyoji Takashi Anayama et al.

Source: CHEST. Jun2016, Vol. 149 Issue 6, p1393-1399. 7p.

Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer.

Authors: Takiguchi, Yuichi Iwasawa, Shunichiro Minato, Koichi et al.

Source: International Journal of Clinical Oncology. Aug2015, Vol. 20 Issue 4, p659-667. 9p.

ALK fusion gene positive lung cancer and 3 cases treated with an inhibitor for ALK kinase activity

Authors: Kimura, Hideki Nakajima, Takahiro Takeuchi, Kengo et al.

Source: Lung Cancer (01695002). Jan2012, Vol. 75 Issue 1, p66-72. 7p.

Comparison of 21-gauge and 22-gauge aspiration needle during endobronchial ultrasound-guided transbronchial needle aspiration.

Authors: Nakajima, Takahiro Yasufuku, Kazuhiro Takahashi, Ryo et al.

Source: Respirology. Jan2011, Vol. 16 Issue 1, p90-94. 5p. 3 Color Photographs, 1 Chart.

MO45-1 Osimertinib vs. erlotinib + bevacizumab or ramucirumab for EGFR mutated NSCLC; a retrospective study from LC-SCRUM-Asia.

Authors: Kagawa, Yosuke Nosaki, Kaname Matsumoto, Shingo et al.

Source: Annals of Oncology. 2022 Supplement 6, Vol. 33, pS510-S510. 1p.

PS1-2 CLIP1-LTK: a novel target in non-small cell lung cancer.

Authors: Izumi, Hiroki Matsumoto, Shingo Mori, Shunta et al.

Source: Annals of Oncology. 2022 Supplement 6, Vol. 33, pS464-S464. 1p.